scholarly journals Global, regional, and national burdens of bladder cancer in 2017: estimates from the 2017 Global Burden of Disease study

2020 ◽  
Author(s):  
Hairong He ◽  
Hongjun Xie ◽  
Yule Chen ◽  
Chengzhuo Li ◽  
Didi Han ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Latin America ◽  
Burden Of Disease ◽  
Western Europe ◽  
Mortality Rates ◽  
Global Burden Of Disease ◽  
Global Burden ◽  
Life Years ◽  
Using Data ◽  
Disease Study

Abstract Background The aim of this study is to describe the prevalence and mortality rates of bladder cancer (BCa) using data obtained in the Global Burden of Disease study performed in 2017 (GBD 2017). Methods Data on BCa for 2017, including prevalence, mortality, and disability-adjusted life years (DALYs), were obtained from GBD 2017 at the global, regional, and national levels. We also analyzed the association of BCa burden with the country development level. Results There were 2.63 million BCa cases estimated from the GBD 2017 data, with 200,000 persons dying of BCa, resulting in 3.60 million DALYs in 2017. The age-standardized prevalence rate (ASPR) of BCa was 32.91/100,000 persons, and age-standardized death rate (ASDR) was 2.57/100,000 persons. The ASPR and ASDR of BCa were higher in males than in females, and higher in people older than 60 years. The ASPR and ASDR of BCa were higher in Western Europe and Central Europe than in South Asia, Andean Latin America, and Central Latin America, and higher in countries with a higher sociodemographic index (SDI). Correlation analysis identified that the ASPR and ASDR of BCa were positively correlated with the country SDI (P < 0.0001 and ρ = 0.68 for ASPR, and P = 0.0048 and ρ = 0.20 for ASDR). Smoking was the main risk factors attributable to the BCa burden. Conclusion The prevalence and mortality rates of BCa were very high in 2017, especially in high-SDI countries. Smoking-cessation strategies should be strengthened to control the burden associated with BCa.

scholarly journals Global, regional, and national burdens of bladder cancer in 2017: estimates from the 2017 global burden of disease study

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Hairong He ◽  
Hongjun Xie ◽  
Yule Chen ◽  
Chengzhuo Li ◽  
Didi Han ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Latin America ◽  
Burden Of Disease ◽  
Western Europe ◽  
Global Burden Of Disease ◽  
Global Burden ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Using Data ◽  
Disease Study

Abstract Background The aim of this study is to describe the prevalence and mortality of bladder cancer (BCa) using data obtained in the Global Burden of Disease study performed in 2017 (GBD 2017). Methods Data on BCa for 2017, including prevalence, mortality, and disability-adjusted life years (DALYs), were obtained from GBD 2017 at the global, regional, and national levels. We also analyzed the association of BCa burden with the country development level. Results There were 2.63 million BCa cases estimated from the GBD 2017 data, with 200,000 persons dying of BCa, resulting in 3.60 million DALYs in 2017. The age-standardized prevalence (ASP) of BCa was 32.91/100,000 persons, and age-standardized death rate (ASDR) was 2.57/100,000 persons. The ASP and ASDR of BCa were higher in males than in females, and higher in people older than 60 years. The ASP and ASDR of BCa were higher in Western Europe and Central Europe than in South Asia, Andean Latin America, and Central Latin America, and higher in countries with a higher sociodemographic index (SDI). Correlation analysis identified that the ASP and ASDR of BCa were positively correlated with the country SDI (P < 0.0001 and ρ = 0.68 for ASP, and P = 0.0048 and ρ = 0.20 for ASDR). In addition, 33.72% deaths and 36.80% DALYs caused by BCa could be attributed to smoking globally. Conclusion The prevalence and mortality of BCa were very high in 2017, especially in high-SDI countries. Smoking-cessation strategies should be strengthened to control the burden associated with BCa.

scholarly journals Global, regional, and national burdens of bladder cancer in 2017: estimates from the 2017 Global Burden of Disease study

2020 ◽  
Author(s):  
Hairong He ◽  
Hongjun Xie ◽  
Yule Chen ◽  
Chengzhuo Li ◽  
Didi Han ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Latin America ◽  
Burden Of Disease ◽  
Western Europe ◽  
Global Burden Of Disease ◽  
Global Burden ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Using Data ◽  
Disease Study

Abstract Background: The aim of this study is to describe the prevalence and mortality of bladder cancer (BCa) using data obtained in the Global Burden of Disease study performed in 2017 (GBD 2017).Methods: Data on BCa for 2017, including prevalence, mortality, and disability-adjusted life years (DALYs), were obtained from GBD 2017 at the global, regional, and national levels. We also analyzed the association of BCa burden with the country development level.Results: There were 2.63 million BCa cases estimated from the GBD 2017 data, with 200,000 persons dying of BCa, resulting in 3.60 million DALYs in 2017. The age-standardized prevalence (ASP) of BCa was 32.91/100,000 persons, and age-standardized death rate (ASDR) was 2.57/100,000 persons. The ASP and ASDR of BCa were higher in males than in females, and higher in people older than 60 years. The ASP and ASDR of BCa were higher in Western Europe and Central Europe than in South Asia, Andean Latin America, and Central Latin America, and higher in countries with a higher sociodemographic index (SDI). Correlation analysis identified that the ASP and ASDR of BCa were positively correlated with the country SDI (P<0.0001 and ρ=0.68 for ASP, and P=0.0048 and ρ=0.20 for ASDR). In addition, 33.72% deaths and 36.80% DALYs caused by BCa could be attributed to smoking globally.Conclusion: The prevalence and mortality of BCa were very high in 2017, especially in high-SDI countries. Smoking-cessation strategies should be strengthened to control the burden associated with BCa.

scholarly journals Global, regional, and national burdens of bladder cancer in 2017: estimates from the 2017 Global Burden of Disease study

2020 ◽  
Author(s):  
Hairong He ◽  
Hongjun Xie ◽  
Yule Chen ◽  
Chengzhuo Li ◽  
Didi Han ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Latin America ◽  
Burden Of Disease ◽  
Western Europe ◽  
Global Burden Of Disease ◽  
Global Burden ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Using Data ◽  
Disease Study

Abstract Background: The aim of this study is to describe the prevalence and mortality of bladder cancer (BCa) using data obtained in the Global Burden of Disease study performed in 2017 (GBD 2017).Methods: Data on BCa for 2017, including prevalence, mortality, and disability-adjusted life years (DALYs), were obtained from GBD 2017 at the global, regional, and national levels. We also analyzed the association of BCa burden with the country development level.Results: There were 2.63 million BCa cases estimated from the GBD 2017 data, with 200,000 persons dying of BCa, resulting in 3.60 million DALYs in 2017. The age-standardized prevalence (ASP) of BCa was 32.91/100,000 persons, and age-standardized death rate (ASDR) was 2.57/100,000 persons. The ASP and ASDR of BCa were higher in males than in females, and higher in people older than 60 years. The ASP and ASDR of BCa were higher in Western Europe and Central Europe than in South Asia, Andean Latin America, and Central Latin America, and higher in countries with a higher sociodemographic index (SDI). Correlation analysis identified that the ASP and ASDR of BCa were positively correlated with the country SDI (P<0.0001 and ρ=0.68 for ASP, and P=0.0048 and ρ=0.20 for ASDR). In addition, 33.72% deaths and 36.80% DALYs caused by BCa could be attributed to smoking globally.Conclusion: The prevalence and mortality of BCa were very high in 2017, especially in high-SDI countries. Smoking-cessation strategies should be strengthened to control the burden associated with BCa.

scholarly journals National burden of cancer in Italy, 1990–2017: a systematic analysis for the global burden of disease study 2017

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Cristina Bosetti ◽  
Eugenio Traini ◽  
Tahiya Alam ◽  
Christine A. Allen ◽  
Giulia Carreras ◽  
...  
Keyword(s):  
Burden Of Disease ◽  
Absolute Number ◽  
Global Burden Of Disease ◽  
Global Burden ◽  
Years Of Life Lost ◽  
Mortality Trends ◽  
Systematic Analysis ◽  
Life Years ◽  
Using Data ◽  
Disease Study

AbstractWe monitored the burden of cancer in Italy and its trends over the last three decades, providing estimates of cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years (DALYs), for cancer overall and 30 cancer sites using data from the Global Burden of Disease study 2017. An overview of mortality trends between 1990 and 2017 was also provided. In 2017, there were 254,336 new cancer cases in men and 214,994 in women, corresponding to an age-standardized incidence rate (ASIR) of 438 and 330/100,000, respectively. Between 1990 and 2017, incident cancer cases, and, to a lesser extent, ASIRs significantly increased overall and for almost all cancer sites, but ASIRs significantly declined for lung and other tobacco-related neoplasms. In 2017, there were 101,659 cancer deaths in men (age-standardized death rate, ASDR, 158.5/100,000) and 78,918 in women (ASDR 93.9/100,000). Cancer deaths significantly increased between 1990 and 2017 (+ 18%), but ASDR significantly decreased (− 28%). Deaths significantly increased for many cancer sites, but decreased for stomach, esophageal, laryngeal, Hodgkin lymphoma, and testicular cancer. ASDRs significantly decreased for most neoplasms, with the main exceptions of cancer of the pancreas and uterus, and multiple myeloma. In 2017, cancer caused 3,204,000 DALYs. Between 1990 and 2017, DALYs and age-standardized DALY rates significantly declined (-3.4% and -33%, respectively). Age-standardized mortality rates in Italy showed favorable patterns over the last few decades. However, the absolute number of cancer cases and, to a lower extent, of cancer deaths increased likely due to the progressive ageing of the population, this calling for a continuous effort in cancer prevention, early diagnosis, and treatment.

scholarly journals Morbidity and mortality from road injuries: results from the Global Burden of Disease Study 2017

2020 ◽  
Vol 26 (Supp 1) ◽  
pp. i46-i56 ◽  
Author(s):  
Spencer L James ◽  
Lydia R Lucchesi ◽  
Catherine Bisignano ◽  
Chris D Castle ◽  
Zachary V Dingels ◽  
...  
Keyword(s):  
Burden Of Disease ◽  
Mortality Rates ◽  
Incidence Rates ◽  
Global Burden Of Disease ◽  
Global Burden ◽  
Years Of Life Lost ◽  
Uncertainty Interval ◽  
Life Years ◽  
Disease Study ◽  
Road Injury

BackgroundThe global burden of road injuries is known to follow complex geographical, temporal and demographic patterns. While health loss from road injuries is a major topic of global importance, there has been no recent comprehensive assessment that includes estimates for every age group, sex and country over recent years.MethodsWe used results from the Global Burden of Disease (GBD) 2017 study to report incidence, prevalence, years lived with disability, deaths, years of life lost and disability-adjusted life years for all locations in the GBD 2017 hierarchy from 1990 to 2017 for road injuries. Second, we measured mortality-to-incidence ratios by location. Third, we assessed the distribution of the natures of injury (eg, traumatic brain injury) that result from each road injury.ResultsGlobally, 1 243 068 (95% uncertainty interval 1 191 889 to 1 276 940) people died from road injuries in 2017 out of 54 192 330 (47 381 583 to 61 645 891) new cases of road injuries. Age-standardised incidence rates of road injuries increased between 1990 and 2017, while mortality rates decreased. Regionally, age-standardised mortality rates decreased in all but two regions, South Asia and Southern Latin America, where rates did not change significantly. Nine of 21 GBD regions experienced significant increases in age-standardised incidence rates, while 10 experienced significant decreases and two experienced no significant change.ConclusionsWhile road injury mortality has improved in recent decades, there are worsening rates of incidence and significant geographical heterogeneity. These findings indicate that more research is needed to better understand how road injuries can be prevented.

scholarly journals India’s Performance in Controlling Visceral Leishmaniasis as Compared to Brazil Over Past Three Decades: Findings From Global Burden of Disease Study

2021 ◽  
Author(s):  
DEEPAK DHAMNETIYA ◽  
Ravi Prakash Jha ◽  
Shalini . ◽  
Krittika Bhattacharyya
Keyword(s):  
Visceral Leishmaniasis ◽  
Burden Of Disease ◽  
Rate Of Change ◽  
Global Burden Of Disease ◽  
Global Burden ◽  
Mortality And Morbidity ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Disease Study ◽  
Incidence Prevalence

Abstract Visceral leishmaniasis (VL) is a neglected tropical disease which contributes to the mortality and morbidity significantly in India and Brazil. This study was planned to compare the trends of incidence, prevalence, death and disability-adjusted life years (DALY) of VL burden in India and Brazil from 1990 to 2019 using Global burden of disease study (GBD) data. The metrics are presented as age-standardized rates per 100,000 inhabitants with their respective uncertainty intervals (95%UI) and relative percentages of change. The decline in the Incidence rate is more in case of India (16.82 cases per 100,000 in 1990 to 0.60cases in 2019) as compared to Brazil (3.12 cases per 100,000 in 1990 to 2.65 cases in 2019). The annualized rate of change in number of prevalent cases for India is -0.95 (95% UI, -0.98 to -0.91) whereas for Brazil it is -0.06 (95% UI, -0.41 to 0.52). The annualized rate of change in number of DALY for India is -0.94 (95% UI, -0.96 to -0.92) whereas for Brazil it is -0.09 (95% UI, -0.25 to 0.28). The annualized rate of change in number of deaths for India is -0.93 (95% UI, -0.95 to -0.92) whereas for Brazil it is increasing i.e. 0.04 (95% UI, -0.12 to 0.51). India achieves significant reduction in the age standardized incidence, prevalence, mortality and DALY of VL as compare to Brazil during the period of 1990 to 2019. A multi-centric study is required to assess bottleneck in the existing strategies of VLSCP in Brazil.

scholarly journals Global, Regional, National, and Subnational Big Data to Inform Health Equity Research: Perspectives from the Global Burden of Disease Study 2017

2019 ◽  
Vol 29 (Suppl 1) ◽  
pp. 159-172 ◽  
Author(s):  
Ali H. Mokdad ◽  
George A. Mensah ◽  
Varsha Krish ◽  
Scott D. Glenn ◽  
Molly K. Miller-Petrie ◽  
...  
Keyword(s):  
Life Expectancy ◽  
Burden Of Disease ◽  
High Body Mass Index ◽  
Global Burden Of Disease ◽  
Global Burden ◽  
Years Of Life Lost ◽  
Healthy Life ◽  
Research Perspectives ◽  
Life Years ◽  
Disease Study

Objectives: Everyone deserves a long and healthy life, but in reality, health outcomes differ across populations. We use results from the Global Burden of Disease Study 2017 (GBD 2017) to report patterns in the burden of diseases, injuries, and risks at the global, regional, national, and subnational level, and by sociodemographic index (SDI), from 1990 to 2017.Design: GBD 2017 undertook a systematic analysis of published studies and available data providing information on prevalence, incidence, remission, and excess mortal­ity. We computed prevalence, incidence, mortality, life expectancy, healthy life expectancy, years of life lost due to prema­ture mortality, years lived with disability, and disability-adjusted life years with 95% uncertainty intervals for 23 age groups, both sexes, and 918 locations, including 195 countries and territories and subnational locations for 16 countries from 1990 to 2017. We also computed SDI, a summary indicator combining measures of income, education, and fertility.Results: There were wide disparities in the burden of disease by SDI, with smaller burdens in affluent countries and in specific regions within countries. Select diseases and risks, such as drug use disorders, high blood pressure, high body mass index, diet, high fasting plasma glucose, smoking, and alco­hol use disorders warrant increased global attention and indicate a need for greater investment in prevention and treatment across the life course.Conclusions: Policymakers need a com­prehensive picture of what risks and causes result in disability and death. The GBD provides the means to quantify health loss: these findings can be used to examine root causes of disparities and develop pro­grams to improve health and health equity.Ethn Dis. 2019;29(Suppl 1): 159-172; doi:10.18865/ed.29.S1.159.

Global, regional, and national burden of other musculoskeletal disorders 1990–2017: results from the Global Burden of Disease Study 2017

Rheumatology ◽  
2020 ◽  
Author(s):  
Saeid Safiri ◽  
Ali Asghar Kolahi ◽  
Marita Cross ◽  
Kristin Carson-Chahhoud ◽  
Amir Almasi-Hashiani ◽  
...  
Keyword(s):  
Burden Of Disease ◽  
National Level ◽  
Point Prevalence ◽  
Global Burden Of Disease ◽  
Global Burden ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Prevalence Estimates ◽  
National Burden ◽  
Disease Study

Abstract Objectives To describe the level and trends of point prevalence, deaths and disability-adjusted life years (DALYs) for other musculoskeletal (MSK) disorders, i.e. those not covered by specific estimates generated for RA, OA, low back pain, neck pain and gout, from 1990 to 2017 by age, sex and sociodemographic index. Methods Publicly available modelled estimates from the Global Burden of Disease (GBD) 2017 study were extracted and reported as counts and age-standardized rates per 100 000 population for 195 countries and territories between 1990 and 2017. Results Globally, the age-standardized point prevalence estimates and deaths rates of other MSK disorders in 2017 were 4151.1 and 1.0 per 100 000. This was an increase of 3.4% and 7.2%, respectively. The age-standardized DALY rate in 2017 was 380.2, an increase of 3.4%. The point prevalence estimate was higher among females and increased with age. This peaked in the 65–69 year age group for both females and males in 2017, followed by a decreasing trend for both sexes. At the national level, the highest age-standardized point prevalence estimates in 2017 were seen in Bangladesh, India and Nepal. The largest increases in age-standardized point prevalence estimates were observed in Romania, Croatia and Armenia. Conclusion The burden of other MSK disorders is proven to be substantial and increasing worldwide, with a notable intercountry variation. Data pertaining to specific diseases within this overarching category are required for future GBD MSK estimates. This would enable policymakers to better allocate resources and provide interventions appropriately.

Sign in / Sign up

Export Citation Format

Share Document